近日，由日本国立癌症研究中心、顺天堂大学等机构组成的研究小组宣布，正式启动了一项新的临床试验，旨在通过移植健康个体的肠道细菌来改善胃癌和食道癌患者的肠道环境，并评估此举能否提高癌症治疗药物的疗效。
该研究小组指出，肠道菌群的失衡可能导致癌症治疗效果不佳。因此，该临床试验计划将健康人群的肠道细菌移植到癌症患者体内，以期恢复和优化患者的肠道微生物群，从而提高免疫治疗药物的效果。
据研究小组介绍，该试验将在未来三年内对最多45名胃癌和食道癌患者进行。这些患者在常规治疗和药物使用前，将接受肠道细菌移植。研究小组将对移植的安全性和有效性进行严格监控，以评估肠道细菌移植在治疗消化系统癌症中的潜力。
这一临床试验在日本国内尚属首次，有望为癌症治疗提供新的策略。研究小组表示，他们将密切关注试验结果，并与其他研究者分享数据，以促进这一领域的研究和实践。
这一试验的启动，不仅是对现有癌症治疗方法的补充，也是对肠道菌群与癌症治疗之间关系研究的进一步探索。未来，如果试验结果积极，肠道细菌移植有望成为癌症治疗的一种新的有效手段。
英语如下：
News Title: “First Case: Japan Tests Intestinal Microbiota Transplantation to Improve Gastric Cancer Treatment”
Keywords: Intestinal Microbiota Transplantation, Cancer Treatment, Clinical Trial
News Content:
Title: Japan’s National Cancer Center Starts Intestinal Microbiota Transplantation for Cancer Treatment Clinical Trial
Recently, a research team consisting of the National Cancer Center of Japan, Shinshu University, and other institutions announced the initiation of a new clinical trial aimed at improving the intestinal environment of patients with gastric and esophageal cancer by transplanting the intestinal bacteria of healthy individuals, and assessing whether this approach can enhance the efficacy of cancer treatment drugs.
The research team pointed out that an imbalance in the gut microbiome can lead to poor treatment outcomes for cancer. Therefore, the clinical trial plans to transplant the intestinal bacteria of healthy individuals into cancer patients in order to restore and optimize their intestinal microbiome, thereby enhancing the efficacy of immunotherapy drugs.
According to the research team, the trial will involve up to 45 patients with gastric and esophageal cancer over the next three years. These patients will undergo intestinal microbiota transplantation before receiving conventional treatments and medications. The research team will strictly monitor the safety and efficacy of the transplant to evaluate the potential of intestinal microbiota transplantation in the treatment of digestive system cancers.
This clinical trial is the first of its kind in Japan and is expected to provide a new strategy for cancer treatment. The research team stated that they will closely monitor the results of the trial and share data with other researchers to promote research and practice in this field.
The initiation of this trial not only supplements existing cancer treatment methods but also further explores the relationship between the gut microbiome and cancer treatment. If the trial results are positive, intestinal microbiota transplantation could become a new and effective treatment for cancer.
【来源】https://nwapi.nhk.jp/nhkworld/rdnewsweb/v6b/zh/detail/20240818_RS08.json
Views: 1